A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder

Abstract Background Major depressive disorder is a common condition that often includes cognitive dysfunction. A systematic literature review of studies and a network meta-analysis were carried out to assess the relative effect of antidepressants on cognitive dysfunction in major depressive disorder. Methods MEDLINE, Embase, Cochrane, CDSR, and PsychINFO databases; clinical trial registries; and relevant conference abstracts were searched for randomized controlled trials assessing the effects of antidepressants/placebo on cognition. A network meta-analysis comparing antidepressants was conducted using a random effects model. Results The database search retrieved 11337 citations, of which 72 randomized controlled trials from 103 publications met the inclusion criteria. The review identified 86 cognitive tests assessing the effect of antidepressants on cognitive functioning. However, the Digit Symbol Substitution Test, which targets multiple domains of cognition and is recognized as being sensitive to change, was the only test that was used across 12 of the included randomized controlled trials and that allowed the construction of a stable network suitable for the network meta-analysis. The interventions assessed included selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and other non-selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors. The network meta-analysis using the Digit Symbol Substitution Test showed that vortioxetine was the only antidepressant that improved cognitive dysfunction on the Digit Symbol Substitution Test vs placebo {standardized mean difference: 0.325 (95% CI = 0.120; 0.529, P=.009}. Compared with other antidepressants, vortioxetine was statistically more efficacious on the Digit Symbol Substitution Test vs escitalopram, nortriptyline, and the selective serotonin reuptake inhibitor and tricyclic antidepressant classes. Conclusions This study highlighted the large variability in measures used to assess cognitive functioning. The findings on the Digit Symbol Substitution Test indicate differential effects of various antidepressants on improving cognitive function in patients with major depressive disorder.

[1]  J. Jaeger,et al.  P.1.j.033 The digit symbol substitution test (DSST): psychometric properties and clinical utility in major depressive disorder , 2016, European Neuropsychopharmacology.

[2]  R. McIntyre,et al.  The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials , 2016, The international journal of neuropsychopharmacology.

[3]  B. Baune,et al.  A review on the impact of cognitive dysfunction on social, occupational, and general functional outcomes in bipolar disorder , 2015, Bipolar disorders.

[4]  R. McIntyre,et al.  The Cognitive Effects of Antidepressants in Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Clinical Trials , 2015, The international journal of neuropsychopharmacology.

[5]  G. Papakostas,et al.  Understanding and managing Cognition in the Depressed Patient. , 2015, The Journal of clinical psychiatry.

[6]  C. Sánchez,et al.  Treatment of cognitive dysfunction in major depressive disorder--a review of the preclinical evidence for efficacy of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors and the multimodal-acting antidepressant vortioxetine. , 2015, European journal of pharmacology.

[7]  J. Zajecka,et al.  A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder , 2015, Neuropsychopharmacology.

[8]  S. Nasr,et al.  Prescriber's Guide to Using 3 New Antidepressants: Vilazodone, Levomilnacipran, Vortioxetine , 2015 .

[9]  B. Baune,et al.  Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression – A systematic review , 2014, Psychiatry Research.

[10]  Charles R. Yang,et al.  Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus , 2014, Journal of psychopharmacology.

[11]  P. Doraiswamy,et al.  Cognitive effects of pharmacotherapy for major depressive disorder: a systematic review. , 2014, The Journal of clinical psychiatry.

[12]  D. Morilak,et al.  Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats , 2014, The international journal of neuropsychopharmacology.

[13]  R. McIntyre,et al.  A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults , 2014, The international journal of neuropsychopharmacology.

[14]  M. Phillips,et al.  Amygdala and whole‐brain activity to emotional faces distinguishes major depressive disorder and bipolar disorder , 2013, Bipolar disorders.

[15]  G. Freedman,et al.  Burden of Depressive Disorders by Country, Sex, Age, and Year: Findings from the Global Burden of Disease Study 2010 , 2013, PLoS medicine.

[16]  J. Roiser,et al.  Cognitive impairment in depression: a systematic review and meta-analysis , 2013, Psychological Medicine.

[17]  P. Celada,et al.  P.2.e.003 Role of 5-HT3 receptors in the mechanism of action of the investigational antidepressant vortioxetine , 2013, European Neuropsychopharmacology.

[18]  B. Baune,et al.  Short- and long-term relationships between neurocognitive performance and general function in bipolar disorder , 2013, Journal of clinical and experimental neuropsychology.

[19]  Janet B W Williams Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[20]  R. Lee,et al.  A meta-analysis of cognitive deficits in first-episode Major Depressive Disorder. , 2012, Journal of affective disorders.

[21]  C. Sánchez,et al.  P.2.h.002 Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition , 2012, European Neuropsychopharmacology.

[22]  Cornelius Katona,et al.  A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder , 2012, International clinical psychopharmacology.

[23]  Michael F. Green,et al.  The FDA-NIMH-MATRICS guidelines for clinical trial design of cognitive-enhancing drugs: what do we know 5 years later? , 2011, Schizophrenia bulletin.

[24]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[25]  B. Baune,et al.  Specifying the Neuropsychology of Affective Disorders: Clinical, Demographic and Neurobiological Factors , 2011, Neuropsychology Review.

[26]  P. de Jonge,et al.  Presence of individual (residual) symptoms during depressive episodes and periods of remission: a 3-year prospective study , 2010, Psychological Medicine.

[27]  B. Baune,et al.  The role of cognitive impairment in general functioning in major depression , 2010, Psychiatry Research.

[28]  A. Rush,et al.  Health-related quality of life in depression: a STAR*D report. , 2010, Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists.

[29]  Donatella Marazziti,et al.  Cognitive impairment in major depression. , 2010, European journal of pharmacology.

[30]  Å. Hammar,et al.  Cognitive Functioning in Major Depression – A Summary , 2009, Front. Hum. Neurosci..

[31]  G. Kaprinis,et al.  Prediction and prevention of suicide in patients with unipolar depression and anxiety , 2007, Annals of general psychiatry.

[32]  R. Porter,et al.  Neuropsychological Impairment in Major Depression: Its Nature, Origin and Clinical Significance , 2007, The Australian and New Zealand journal of psychiatry.

[33]  C. Mathers,et al.  Projections of Global Mortality and Burden of Disease from 2002 to 2030 , 2006, PLoS medicine.

[34]  G. Turecki,et al.  Suicide Cases in New Brunswick from April 2002 to May 2003: The Importance of Better Recognizing Substance and Mood Disorder Comorbidity , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[35]  K. Hugdahl,et al.  Neuropsychological test profiles in schizophrenia and non‐psychotic depression , 2006, Acta psychiatrica Scandinavica.

[36]  J. Tignol,et al.  Double‐blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major dipressive episode , 1998 .

[37]  M. Boyle,et al.  P-12-35 Utility-based measures of health-related quality of life in depression , 1996, European Neuropsychopharmacology.

[38]  F. Artigas,et al.  Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. , 2015, Pharmacology & therapeutics.

[39]  A. Carvalho,et al.  The impact of cognitive impairment on perceived workforce performance: results from the International Mood Disorders Collaborative Project. , 2015, Comprehensive psychiatry.

[40]  B. Mulsant,et al.  The MMSE is not an adequate screening cognitive instrument in studies of late-life depression. , 2009, Journal of psychiatric research.

[41]  J. Tignol,et al.  Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. , 1998, Acta psychiatrica Scandinavica.